Brand Engagement Network Inc. (BNAI) shares climbed Monday after the company locked down a Vendor Services Project Agreement with a prominent global advertising agency. The deal? Building a custom AI engagement solution for a top-10 global pharmaceutical company's prescription drug.

The client and agency names are being kept under wraps for now, with identities to be revealed after a formal product release. But the financial details are clear enough: Brand Engagement Network will book $250,000 in development revenue during the fourth quarter of 2025, then start collecting ongoing monthly licensing fees beginning in the first quarter of 2026.

This new revenue stream arrives at a convenient time. Combined with the company's recent move to launch Skye Salud in Mexico and its Latin American licensing partnership, the deal is expected to fuel growth as the 2025 fiscal year wraps up. It's all part of a broader pattern showing increased confidence in Brand Engagement Network's proprietary AI technology across both U.S. and Mexican markets.

Management Weighs In

Tyler Luck, acting CEO of BEN, said the agreement highlights the company's expanding presence in healthcare, where its platform delivers "trusted, secured, and efficient AI" for pharmaceutical manufacturers, healthcare providers, and patients. He emphasized that the deal reinforces BEN's commitment to building consumer experiences centered on accuracy, reliability, and integrity.

Cleaning Up the Balance Sheet

Last week, the company announced it had slashed roughly $2.5 million from its total liabilities for the fourth quarter of 2025. The reduction came through a combination of negotiated settlements, direct payments, and debt-to-equity conversions—essentially tidying up the books heading into the new year.

BNAI Price Action: Brand Engagement Network shares were up 20.00% at $1.44 during premarket trading on Monday.